Medium-Throughput Drug- and Radiotherapy Screening Assay using Patient-Derived Organoids.
Hans Clevers , Maurice M J M Zandvliet , Marrit Putker , René Overmeer
Journal of Visualized Experiments ( 170)
6
2021
CD8+ tumor‐infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival
Rosemary Millen , Shona Hendry , Vignesh Narasimhan , Rebecca Abbott
Clinical And Translational Immunology 9 ( 7)
1
2020
Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.
Maria Bolther , Karen Lise Dahl Andersen , Martin Tolstrup , Kumar Visvanathan
Human Vaccines & Immunotherapeutics 14 ( 6) 1483 -1488
1
2018
MAIT cells regulate NK cell mediated tumor immunity
Emma V Petley , Hui-Fern Koay , Melissa A Henderson , Kevin Sek
26
2020
Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer
Rosemary Millen , Jordane Malaterre , Ryan S. Cross , Sandra Carpinteri
OncoImmunology 5 ( 7)
6
2016
Evaluating and manipulating the immune landscape in hepatic verses peritoneal metastases arising from colorectal primary tumors.
Robert George Ramsay , Rosemary Millen , Vignesh Narasimhan , Sara Roth
Journal of Clinical Oncology 37 ( 4) 568 -568
2019
Rapid tissue prototyping with micro-organospheres
Zhaohui Wang , Matteo Boretto , Rosemary Millen , Naveen Natesh
Stem cell reports 17 ( 9) 1959 -1975
2
2022
Patient-derived micro-organospheres enable clinical precision oncology
Shengli Ding , Carolyn Hsu , Zhaohui Wang , Naveen R Natesh
Cell Stem Cell 29 ( 6) 905 -917
21
2022
Uncovering the mode of action of engineered T cells in patient cancer organoids
Johanna F Dekkers , Maria Alieva , Astrid Cleven , Farid Keramati
Nature biotechnology 41 ( 1) 60 -69
69
2023
Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification
Rosemary Millen , Willem WB De Kort , Mandy Koomen , Gijs JF van Son
Med 4 ( 5) 290 -310. e12
16
2023
Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
Patricia Hernández-López , Eline van Diest , Peter Brazda , Sabine Heijhuurs
Nature Immunology 25 ( 1) 88 -101
2
2024
Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7
Matteo Boretto , Maarten H Geurts , Shashank Gandhi , Ziliang Ma
Proceedings of the National Academy of Sciences 121 ( 12) e2309902121 -e2309902121
2024
Combining targeting of the cancer metabolome and cancer-associated stress antigens impacts engineered T cell dynamics and efficacy
Patricia Hernández-López , Eline van Diest , Peter Brazda , Inez Johanna
Immunotherapy with T cells: new strategies and improved designs 55 -55
Hepatitis B Virus Flares After Nucleot (s) ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel AL Hall , Gareth S Burns , Benjamin J Mooney , Rosemary Millen
The Journal of infectious diseases 227 ( 1) 123 -132
3
2023
Hepatitis B Virus Flares After Nucleot (s) ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways
Samuel Al Hall , Gareth S Burns , Benjamin J Mooney , Rosemary Millen
JOURNAL OF INFECTIOUS DISEASES 227 ( 1) 123 -132
2022
SB 9200 Shows Antiviral Activity Against HCV-RNA by Targeting Host Cytosolic Sensor Proteins RIG-I and NOD-2 to activate IFN signaling pathways
Kumar Visvanathan , Rosemary Millen , Stuart K Roberts , Peter W Angus
Platelets (x109/L) 250 14.9 -14.9
2015
S201: Final 7-year follow up and retreatment substudy analysis of murano: venetoclax-rituximab (venr)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)
Arnon Kater , Rosemary Harrup , Thomas J Kipps , Barbara Eichhorst
HemaSphere 7 e492813f -e492813f
6
2023
Long-term host immune changes following treatment with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia
Arnon P Kater , Barbara Eichhorst , Carolyn Owen , Ulrich Jaeger
Blood 140 ( Supplement 1) 7010 -7012
1
2022
Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab
Rosemary Anne Harrup , Arnon P Kater , Barbara F Eichhorst , Carolyn Owen
Blood 142 1898 -1898
2023
Results: landmark PFS and OS after initiation of next-line therapy
Rosemary Harrup , Arnon P Kater , Barbara Eichhorst , Carolyn Owen